Donepezil in Alzheimer’s Disease: What to Expect after 3 Years of Treatment in a Routine Clinical Setting
Authors:
- Åsa K. WallinÅWÅsa K. Wallin
- Niels AndreasenNANiels Andreasen
- Sture ErikssonSESture Eriksson
- Stellan BåtsmanSBStellan Båtsman
- Birgitta NäsmanBNBirgitta Näsman
- Anne EkdahlAEAnne Ekdahl
- Lena KilanderLKLena Kilander
- Mikaela GrutMGMikaela Grut
- Marie RydénMRMarie Rydén
- Anders WallinAWAnders Wallin
- Mikael JonssonMJMikael Jonsson
- Hasse OlofssonHOHasse Olofsson
- 18 December 2006
- journal article
- clinical trial
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 23 (3) , 150-160
Abstract
Background/Aims: Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer’s disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated. Methods: The Swedish Alzheimer Treatment Study (SATS) is a descriptive, prospective, longitudinal, multicentre study. Four hundred and thirty-five outpatients with the clinical diagnosis of Alzheimer’s disease, received treatment with donepezil. Patients were assessed with Mini-Mental State Examination (MMSE), Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog), global rating (CIBIC) and Instrumental Activities of Daily Living (IADL) at baseline and every 6 months for a total period of 3 years. Results: The mean MMSE change from baseline was positive for more than 6 months and in subgroups of patients for 12 months. After 3 years of treatment the mean change from baseline in MMSE-score was 3.8 points (95% CI, 3.0–4.7) and the ADAS-cog rise was 8.2 points (95% CI, 6.4–10.1). This is better than expected in untreated historical cohorts, and better than the ADAS-cog rise calculated by the Stern equation (15.6 points; 95% CI, 14.5–16.6). After 3 years with 38% of the patients remaining, 30% of the them were unchanged or improved in the global assessment. Conclusion: Three-year donepezil treatment showed a positive global and cognitive outcome in the routine clinical setting.Keywords
This publication has 39 references indexed in Scilit:
- Donepezil for dementia due to Alzheimer's diseaseCochrane Database of Systematic Reviews, 2006
- Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Differential Efficacy of Treatment with Acetylcholinesterase Inhibitors in Patients with Mild and Moderate Alzheimer’s Disease over a 6-Month PeriodDementia and Geriatric Cognitive Disorders, 2005
- Long‐term efficacy and safety of galantamine in patients with mild‐to‐moderate Alzheimer's disease: multicenter trialEuropean Journal of Neurology, 2004
- Five-Year Outcome of Cholinergic Treatment of Alzheimer’s Disease: Early Response Predicts Prolonged Time until Nursing Home Placement, but Does Not Alter Life ExpectancyDementia and Geriatric Cognitive Disorders, 2004
- Disease Stage in Alzheimer Disease and Treatment Effects of RivastigmineAlzheimer Disease & Associated Disorders, 2004
- Oral Tetrahydroaminoacridine Treatment of Alzheimer's Disease Evaluated Clinically and by Regional Cerebral Blood Flow and EEGDementia and Geriatric Cognitive Disorders, 1993
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.BMJ, 1978
- Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily LivingThe Gerontologist, 1969